ATE458051T1 - Low density lipoprotein-bindende proteine und deren verwendung in der diagnostik und behandlung von atherosklerose - Google Patents

Low density lipoprotein-bindende proteine und deren verwendung in der diagnostik und behandlung von atherosklerose

Info

Publication number
ATE458051T1
ATE458051T1 AT01916279T AT01916279T ATE458051T1 AT E458051 T1 ATE458051 T1 AT E458051T1 AT 01916279 T AT01916279 T AT 01916279T AT 01916279 T AT01916279 T AT 01916279T AT E458051 T1 ATE458051 T1 AT E458051T1
Authority
AT
Austria
Prior art keywords
atherosclerosis
methods
low density
density lipoprotein
binding proteins
Prior art date
Application number
AT01916279T
Other languages
English (en)
Inventor
Ann Lees
Robert Lees
Simon Law
Anibal Arjona
Original Assignee
Boston Heart Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/517,849 external-priority patent/US6605588B1/en
Application filed by Boston Heart Foundation Inc filed Critical Boston Heart Foundation Inc
Application granted granted Critical
Publication of ATE458051T1 publication Critical patent/ATE458051T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
AT01916279T 2000-03-02 2001-02-28 Low density lipoprotein-bindende proteine und deren verwendung in der diagnostik und behandlung von atherosklerose ATE458051T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/517,849 US6605588B1 (en) 1996-11-27 2000-03-02 Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis
US09/616,289 US6632923B1 (en) 1996-11-27 2000-07-14 Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis
PCT/US2001/006356 WO2001064874A2 (en) 2000-03-02 2001-02-28 Low density liprotein binding proteins and their use in diagnosing and treating atherosclerosis

Publications (1)

Publication Number Publication Date
ATE458051T1 true ATE458051T1 (de) 2010-03-15

Family

ID=27059254

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01916279T ATE458051T1 (de) 2000-03-02 2001-02-28 Low density lipoprotein-bindende proteine und deren verwendung in der diagnostik und behandlung von atherosklerose

Country Status (7)

Country Link
US (7) US6632923B1 (de)
EP (1) EP1263954B1 (de)
JP (1) JP2003525608A (de)
AT (1) ATE458051T1 (de)
AU (1) AU2001243322A1 (de)
DE (1) DE60141323D1 (de)
WO (1) WO2001064874A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001093902A2 (en) * 2000-06-07 2001-12-13 Biosynexus Incorporated Immunostimulatory rna/dna hybrid molecules
JP2004524030A (ja) * 2001-02-23 2004-08-12 ザ ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン 膵臓がんにおけるメチル化の異なる配列
JP2003308030A (ja) 2002-02-18 2003-10-31 Sanyo Electric Co Ltd 表示装置
US20110177610A1 (en) * 2007-06-18 2011-07-21 Sekisui Medical Co., Ltd. Novel marker for arteriosclerotic disease
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) * 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) * 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7678444B2 (en) 2007-12-17 2010-03-16 International Paper Company Thermoformed article made from renewable polymer and heat-resistant polymer
US20090274920A1 (en) * 2008-05-05 2009-11-05 International Paper Company Thermoformed Article Made From Bio-Based Biodegradable Polymer Composition
WO2011071666A1 (en) 2009-12-08 2011-06-16 International Paper Company Thermoformed articles made from reactive extrusion products of biobased materials
LU103244B1 (en) * 2024-02-14 2025-08-14 Univ Hamburg Eppendorf Uke Deletion of the mouse homolog of human FHR1 (FHRE) protects ApoE-/- mice from atherosclerosis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59206046A (ja) 1983-05-11 1984-11-21 Asahi Chem Ind Co Ltd 低比重リポ蛋白質を吸着する材料
US4660563A (en) 1984-12-31 1987-04-28 Massachusetts Institute Of Technology Method and means for detection of arterial lesions
US4877599A (en) * 1986-11-10 1989-10-31 New England Deaconess Hospital Corporation Detection of vascular disease with labelled antibodies
US5726153A (en) * 1988-05-02 1998-03-10 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
ZA893740B (en) * 1988-06-03 1990-02-28 Hoffmann La Roche Recombinant coccidiosis vaccines
US5135848A (en) 1989-10-23 1992-08-04 Lehigh University And Northeast Benjamin Franklin Technology Center Of Pa Methods for evaluating cholesterol metabolism and reagents therefor
US5196324A (en) * 1989-12-15 1993-03-23 Eli Lilly And Company Monoclonal antibodies reactive with a human atheroma associated antigen
JPH05507276A (ja) 1990-05-03 1993-10-21 ニュー・イングランド・ディーコネス・ホスピタル・コーポレイション 動脈造影用合成ペプチド類
US5399338A (en) * 1991-05-01 1995-03-21 University Of New Mexico Enhancement of abnormal tissue uptake of antibodies, tumor-specific agents or conjugates thereof for diagnostic imaging or therapy
DE4222385A1 (de) * 1992-07-08 1994-01-13 Boehringer Ingelheim Int Verfahren zur Isolierung von Inhibitoren des Rhinovirus-Rezeptors
EP0586094A1 (de) 1992-08-03 1994-03-09 Wisconsin Alumni Research Foundation Löslicher LDL-Rezeptor und Gen
AU6234194A (en) 1993-01-15 1994-08-15 Board Of Regents, The University Of Texas System High molecular weight b-cell growth factor: interleukin-14
US5698686A (en) 1994-10-20 1997-12-16 Arch Development Corporation Yeast telomerase compositions
US6177614B1 (en) * 1995-03-16 2001-01-23 Cold Spring Harbor Laboratory Control of floral induction in plants and uses therefor
JPH09163988A (ja) 1995-10-09 1997-06-24 Kowa Co 新規なｌｄｌ受容体類似蛋白質及び遺伝子
EP0969855B1 (de) 1996-11-27 2006-02-08 Boston Heart Foundation, Inc. Neue low density lipoprotein bindende proteine und deren verwendung in der diagnostik und behandlung von atherosklerose
US9612811B2 (en) * 2014-01-21 2017-04-04 Nvidia Corporation Confluence analysis and loop fast-forwarding for improving SIMD execution efficiency

Also Published As

Publication number Publication date
WO2001064874A3 (en) 2002-02-14
US6878817B2 (en) 2005-04-12
US20100028327A1 (en) 2010-02-04
DE60141323D1 (de) 2010-04-01
AU2001243322A1 (en) 2001-09-12
EP1263954A2 (de) 2002-12-11
EP1263954B1 (de) 2010-02-17
WO2001064874A9 (en) 2003-02-06
US20040040049A1 (en) 2004-02-26
WO2001064874A2 (en) 2001-09-07
US20020194633A1 (en) 2002-12-19
US7807384B2 (en) 2010-10-05
JP2003525608A (ja) 2003-09-02
US7402395B2 (en) 2008-07-22
US20020152485A1 (en) 2002-10-17
US7244410B2 (en) 2007-07-17
US6632923B1 (en) 2003-10-14
US20020129388A1 (en) 2002-09-12
US20040013668A1 (en) 2004-01-22

Similar Documents

Publication Publication Date Title
ATE458051T1 (de) Low density lipoprotein-bindende proteine und deren verwendung in der diagnostik und behandlung von atherosklerose
Ripamonti et al. Long‐term evaluation of bone formation by osteogenic protein 1 in the baboon and relative efficacy of bone‐derived bone morphogenetic proteins delivered by irradiated xenogeneic collagenous matrices
Anderson et al. Relationship between intestinal iron-transporter expression, hepatic hepcidin levels and the control of iron absorption
Haberland et al. Scavenger receptor-mediated recognition of maleyl bovine plasma albumin and the demaleylated protein in human monocyte macrophages.
CY1119263T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστων
Cleland et al. Bone protein extraction without demineralization using principles from hydroxyapatite chromatography
EA200100502A1 (ru) СПОСОБЫ И КОМПОЗИЦИЯ ДЛЯ ВОССТАНОВЛЕНИЯ КОНФОРМАЦИОННОЙ СТАБИЛЬНОСТИ БЕЛКА СЕМЕЙСТВА p53
AR006188A1 (es) "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion".
DK0526544T3 (da) Terapeutiske anvendelser af actinbindende forbindelser
BR0015137A (pt) Peptìdeos antigênicos de neisseria
BR0206985A (pt) Anticorpos modificados e métodos de uso
Wilson et al. Proteomic analysis of cartilage proteins
ATE286118T1 (de) Anwendungen für humane nicht autologe, mesenchymale stammzellen
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
DK0690872T3 (da) Biologisk aktive peptider fra funktionelle domæner af baktericidt/permeabilitetsforøgende protein og anvendelser deraf
Maestracci et al. Proteins and glycoproteins of the human intestinal brush border membrane
ATE317264T1 (de) Neue low density lipoprotein bindende proteine und deren verwendung in der diagnostik und behandlung von atherosklerose
Phillips et al. Biomimetic proteoglycans diffuse throughout articular cartilage and localize within the pericellular matrix
Link et al. Chondroitinase ABC enhances integration of self-assembled articular cartilage, but its dosage needs to be moderated based on neocartilage maturity
DE69510356D1 (de) Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
DE60102147D1 (de) Anti-gefrier proteine, deren herstellung und verwendung
Zal et al. Investigation by electrospray ionization mass spectrometry of the extracellular hemoglobin from the polychaete annelid Alvinella pompejana: an unusual hexagonal bilayer hemoglobin
Richardson et al. Comparisons of protein changes in human and rodent hepatocytes induced by the rat‐specific carcinogen, methapyrilene
Rubinacci et al. Bone as an ion exchange system: evidence for a pump-leak mechanism devoted to the maintenance of high bone K+

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties